Developing and communicating effective pathways for patients with sarcoma in London and South East EnglandProduct type:Shared learningPublished: 8 December 2015
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach (IPG717)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 2 March 2022
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 August 2020
GatewayC: Improving early detection of cancer through e-learning for primary careProduct type:Shared learningPublished: 31 January 2019
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 November 2010Published: 27 October 2004
Improving outcomes for people with sarcoma (CSG9)Product type:GuidanceProgramme:Cancer service guidelinePublished: 20 March 2006
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2020
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)Product type:GuidanceProgramme:Clinical guidelineLast updated: 26 April 2023Published: 26 July 2010
Mifamurtide for the treatment of osteosarcoma (TA235)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2011
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) (TA745)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 November 2021
Next-generation sequencing panel for solid tumour cancers in children (MIB133)Product type:AdviceProgramme:Medtech innovation briefingPublished: 8 January 2018
Overcoming the challenges of implementing the new NICE guidance for suspected cancer: recognition and referralProduct type:Shared learningPublished: 8 January 2017
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2017
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 September 2009
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Symptomatic Breast Referral Resource Suite: Enhancing the Suspected Cancer Recognition and Referral ProcessProduct type:Shared learningPublished: 10 November 2020
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 8 February 2021Published: 24 February 2010